Cardiovascular Disease among Syrian refugees: a descriptive study of patients in two Médecins Sans Frontières clinics in northern Lebanon.

Publisher: BioMed Central Country of Publication: England NLM ID: 101286573 Publication Model: eCollection Cited Medium: Print ISSN: 1752-1505 (Print) Linking ISSN: 17521505 NLM ISO Abbreviation: Confl Health Subsets: PubMed not MEDLINE

Original Publication: London : BioMed Central, c2007-

Background: Literature on the burden and management of atherosclerotic cardiovascular disease (ASCVD) in humanitarian settings is limited. This study aimed to describe patient characteristics and explore both service use and use of recommended secondary prevention drugs in Syrian refugee patients with ASCVD attending two Médecins Sans Frontières (MSF) clinics in Lebanon.
Methods: This study comprised a cross-sectional survey of ASCVD patients attending either MSF clinic over a four-week period in early 2017. Using descriptive statistics, we explored patient demographic characteristics, cardiovascular risk factors and assessed ASCVD secondary prevention medication prescription and patient adherence with a 7-day self-report scale. A retrospective study of routine clinical data explored workload and trends in patient loss to follow-up. We performed logistic regression modelling to explore risk factors for loss to follow-up.
Results: We included 514 patients with ASCVD in the cross-sectional study, performed in 2017. Most (61.9%) were male and mean age was 60.4 years (95% CI, 59.6-61.3). Over half (58.8%) underwent revascularization and 26.1% had known cerebrovascular disease. ASCVD risk factors included 51.8% with diabetes and 72.2% with hypertension. While prescription (75.7 to 98.2%) and self-reported adherence rates (78.4 to 93.9%) for individual ASCVD secondary prevention drugs (ACE-inhibitor, statin and antiplatelet) were high, the use of all three was low at 41.3% (CI 95% : 37.0-45.6). The 5-year retrospective cohort study (ending April 2017) identified 1286 patients with ASCVD and 16,618 related consultations (comprising 24% of all NCD consultations). Over one third (39.7%) of patients were lost to follow-up, with lower risk among men.
Conclusions: The burden of ASCVD within MSF clinics in Lebanon is substantial. Although prescription and adherence of individual secondary prevention drugs is acceptable, overall use of the three recommended drugs is suboptimal. Loss to follow-up rates were high. Further studies are needed to evaluate innovative strategies to increase the use of the multiple recommended drugs, and to increase the retention of patients with ASCVD in the care system.
Competing Interests: Competing interestsThe authors declare that they have no competing interests.

Lancet. 2014 Jan 25;383(9914):356-67. (PMID: 24452044)
BMJ Glob Health. 2017 Mar 27;2(2):e000298. (PMID: 28589033)
Ann Intern Med. 2007 Oct 16;147(8):573-7. (PMID: 17938396)
Lancet Glob Health. 2018 Mar;6(3):e292-e301. (PMID: 29433667)
J Gen Intern Med. 2011 Dec;26(12):1479-91. (PMID: 21858602)
PLoS One. 2015 Sep 25;10(9):e0138303. (PMID: 26406317)
Glob Health Sci Pract. 2017 Sep 28;5(3):495-506. (PMID: 28928227)
Prehosp Disaster Med. 2015 Feb;30(1):80-8. (PMID: 25499440)
Heart. 2019 Sep;105(18):1388-1394. (PMID: 31138670)
Lancet Diabetes Endocrinol. 2019 Aug;7(8):638-647. (PMID: 30878268)
Br J Clin Pharmacol. 2014 Mar;77(3):427-45. (PMID: 23803249)
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25. (PMID: 28527533)
PLoS One. 2016 Apr 13;11(4):e0150088. (PMID: 27073930)
Circulation. 2011 Nov 29;124(22):2458-73. (PMID: 22052934)
Lancet. 2017 Sep 16;390(10100):1151-1210. (PMID: 28919116)
Subst Use Misuse. 2017 Sep 19;52(11):1494-1510. (PMID: 28471305)
PLoS Med. 2016 Nov 8;13(11):e1002180. (PMID: 27824879)
JAMA. 2018 Aug 14;320(6):566-579. (PMID: 30120478)
Lancet. 2017 Mar 11;389(10073):1055-1065. (PMID: 28290995)
Tob Control. 2016 Mar;25(2):129-40. (PMID: 25770116)
Thromb Res. 2006;117(6):631-7. (PMID: 15985286)
Confl Health. 2019 Mar 22;13:8. (PMID: 30949232)
BMJ Open. 2016 Nov 30;6(11):e012717. (PMID: 27903562)
Lancet. 2011 Oct 1;378(9798):1231-43. (PMID: 21872920)
Circulation. 2019 Feb 26;139(9):e44-e54. (PMID: 30674212)
Vasc Health Risk Manag. 2012;8:145-50. (PMID: 22454558)
Ther Clin Risk Manag. 2012;8:65-72. (PMID: 22368447)
Heart. 2009 Feb;95(2):125-9. (PMID: 18381374)

Keywords: ASCVD; Adherence; Cardiovascular disease; Humanitarian assistance; Lebanon; Refugee; Secondary prevention; Syria

Date Created: 20190816 Latest Revision: 20240719

20240719

PMC6688221

10.1186/s13031-019-0217-x

31413727